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Background—A panel of experts convened by the American Dental Association (ADA) Council 
on Scientific Affairs presents evidence-based clinical recommendations regarding professionally 
applied and prescription-strength, home-use topical fluoride agents for caries prevention. These 
recommendations are an update of the 2006 ADA recommendations regarding professionally 
applied topical fluoride and were developed by using a new process that includes conducting a 
systematic review of primary studies.
Types of Studies Reviewed—The authors conducted a search of MEDLINE and the Cochrane 
Library for clinical trials of professionally applied and prescription-strength topical fluoride agents
—including mouthrinses, varnishes, gels, foams and pastes—with caries increment outcomes 
published in English through October 2012.
Results—The panel included 71 trials from 82 articles in its review and assessed the efficacy of 
various topical fluoride caries-preventive agents. The panel makes recommendations for further 
research.
Practical Implications—The panel recommends the following for people at risk of developing 
dental caries: 2.26 percent fluoride varnish or 1.23 percent fluoride (acidulated phosphate fluoride) 
gel, or a prescription-strength, home-use 0.5 percent fluoride gel or paste or 0.09 percent fluoride 
mouthrinse for patients 6 years or older. Only 2.26 percent fluoride varnish is recommended for 
children younger than 6 years. The strengths of the recommendations for the recommended 
products varied from “in favor” to “expert opinion for.” As part of the evidence-based approach to 
care, these clinical recommendations should be integrated with the practitioner's professional 
judgment and the patient's needs and preferences.
Keywords
Caries prevention; caries; evidence-based dentistry; fluoride; practice guidelines; preventive 
dentistry
In 2006, the Council on Scientific Affairs (CSA) of the American Dental Association 
(ADA) published recommendations for the use of professionally applied topical fluorides for 
caries prevention.1 It is ADA policy to start updating the evidence and clinical 
recommendations at five-year intervals. The objective of this report is to provide an update 
on professionally applied topical fluorides and address additional questions related to the use 
of prescription-strength, home-use topical fluorides for caries prevention. The panel 
evaluated sodium, stannous and acidulated phosphate fluoride (APF) for professional and 
prescription-strength home-use, including varnishes, gels, foams, mouthrinses and 
prophylaxis pastes. The panel did not include over-the-counter products, slow-release 
delivery devices, dental materials that release fluorides and products that contain sodium 
monofluorophosphate, silver diamine fluoride and titanium tetrafluoride in this report. 
Sodium monofluorophosphate is primarily a nonprescription, daily-use fluoride product. 
Silver diamine fluoride and titanium fluoride are not available in any products in the United 
States. For the remainder of this article, the term “topical fluoride agents” will be used to 
include professionally applied, as well as prescriptionstrength, home-use products.
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The grading system2 used in this report was adapted from the U.S. Preventive Services Task 
Force (USPSTF) system,3 and it differs markedly from the system the previous panel used 
for the 2006 clinical recommendations.1 One difference is that the current clinical 
recommendations are based on a synthesis of primary evidence collected by means of a de 
novo systematic review, whereas the previous clinical recommendations were based 
primarily on published systematic reviews. Another difference is that the current 
recommendations are based on the net benefit of the intervention (that is, a balance of 
benefits with potential harm) in conjunction with the level of certainty in the evidence, 
whereas the 2006 clinical recommendations were based solely on the study design.4 These 
changes have resulted in some modifications to the strengths assigned to the individual 
recommendations for products reviewed in this report compared with recommendations for 
the products reviewed in the 2006 clinical recommendations report.
The current grading system includes the use of expert opinion as a means of determining 
whether to make clinical recommendations when evidence is lacking, contradictory or 
judged to have a high risk of bias (that is, a reliable estimate of the net benefit of the 
intervention is not possible). Practitioners should note the strength of the recommendations 
and endeavor to understand the underlying evidence in terms of the level of certainty and the 
balance of benefits with potential harm. They should discuss uncertainties in evidence with 
their patients, providing awareness that there usually is some level of uncertainty in the 
evidence used for making clinical decisions, in part arising from lack of clinical data, 
changes in product formulations across time and the availability of a wide variety of 
products.
The panel prepared this report to help practitioners make decisions about the use of topical 
fluoride caries preventive agents. (The full report, which includes more details, is available 
at http://ebd.ada.org//ClinicalRecommendations.aspx.) The recommendations in this report 
are not intended to define a standard of care but rather should be integrated with each 
practitioner's professional judgment and each patient's needs and preferences.
METHODS
The ADA CSA convened the panel, which was multidisciplinary and comprised subject 
matter and methodology experts, as well as representatives from various stakeholder groups. 
They addressed two clinical questions:
– In primary and permanent teeth, does the use of a topical fluoride agent reduce the 
incidence of new lesions in coronal caries, root caries or both compared with no topical 
fluoride use?
– Does the use of prophylaxis before application of topical fluoride reduce the incidence 
of caries to a greater extent than the application of topical fluoride without prophylaxis?
In the first part of the process, the authors conducted a systematic review of the literature. 
They then developed evidence statements based on a statistical evaluation of the evidence, 
as well as an assessment of their level of certainty in the statement (high, moderate, low), 
according to a standardized grading system (Table 12,3).
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In the second part of the process, the panel developed clinical recommendations and graded 
the strength of the recommendations, according to a standardized process. The panel 
ascertained the net benefit rating by judging the balance of benefits with potential harm. For 
example, if a topical fluoride agent was found to be effective, and the benefit was judged to 
outweigh the potential harm, the net benefit was “benefit outweighs potential harm.” The 
panel used the information in Table 23 to combine the level of certainty with the net benefit 
rating to arrive at the strength of the recommendation (strong, in favor, weak, expert opinion 
for, expert opinion against or against) to determine the strength of the clinical 
recommendation as defined in Table 1.2,3 Table 33 shows the definitions of these 
recommendation strengths.
The panel approved the clinical recommendations by a simple majority vote. The panel 
sought comments on this report from other subject matter experts, methodologists, 
epidemiologists and end-users before finalizing the recommendations. The ADA CSA 
approved the final report for publication.
CLINICAL RECOMMENDATIONS: SUMMARY
For people who are at an elevated risk of developing dental caries, the panel makes clinical 
recommendations for the use of specific topical fluoride agents (Table 4); these 
recommendations are based on the evidence statements and the balance of benefits with 
potential harm (Table 5,5,6 pages 1284-1285). The panel recommends topical fluoride agents 
only for people what are at elevated risk of developing dental caries.
The panel recommends the following for people at risk of developing dental caries: 2.26 
percent fluoride varnish or 1.23 percent fluoride (APF) gel, or a prescription-strength, home-
use 0.5 percent fluoride gel or paste or 0.09 percent fluoride mouthrinse for patients 6 years 
or older. Only 2.26 percent fluoride varnish is recommended for children younger than 6 
years. The strengths of the recommendations for the recommended products varied from “in 
favor” to “expert opinion for.”
The panel judged that the benefits outweighed the potential for harm for all professionally 
applied and prescription-strength, home-use topical fluoride agents and age groups except 
for children younger than 6 years. In these children, the risk of experiencing adverse events 
(particularly nausea and vomiting) associated with swallowing professionally applied topical 
fluoride agents outweighed the potential benefits of using all of the topical fluoride agents 
except for 2.26 percent fluoride varnish.
DISCUSSION OF EVIDENCE AND CLINICAL RECOMMENDATIONS
The panel included 71 trials in 82 published articles (some clinical studies were published in 
multiple articles) in its review and assessed the efficacy of various topical fluoride agents for 
preventing caries. Table 55,6 (pages 1284-1285) summarizes the expert panel's assessment of 
the evidence. There were some general considerations to take into account when reviewing 
the evidence. First, some of the studies were conducted before the 1970s, when dental caries 
rates among children were higher,7 the percentage of the population receiving fluoridated 
water was substantially lower,8 and the percentage of people using fluoridated dentifrice was 
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much lower.9 Second, some studies were conducted in countries with different caries 
prevalence and different levels of background fluoride exposure and other caries prevention 
efforts. Third, the study populations often could not be categorized in terms of caries risk, 
and the panel could not assign risk categories to the populations as they are defined today. 
Therefore, caution is advised when extrapolating the results to today's high-risk populations, 
such as children at high risk of developing early childhood caries.
Table 6 (page 1286) presents the fluoride concentrations of each of topical fluoride agent 
evaluated, both as a concentration of fluoride ion and a concentration of sodium fluoride.
Varnish
There are more than 30 fluoride-containing varnish products on the market today, and they 
have varying compositions and delivery systems. These compositional differences lead to 
widely variable pharmacokinetics, the effects of which remain largely untested clinically. 
Through the literature search, the panel found clinical trials10-38 regarding four brand-name 
products and decided to summarize the results of these trials on the basis of the percentage 
of fluoride, which was either 2.26 percent or 0.1 percent. Further research revealed that 
products identified with an identical brand name (Fluor Protector, Ivoclar Vivadent, 
Amherst, N.J.) underwent a compositional change in 1987 from 0.7 percent fluoride to 0.1 
percent fluoride.39 Because the 0.7 percent fluoride product no longer is available 
commercially, these trials10-14 were not eligible for inclusion in this review. Therefore, the 
data are subdivided into 2.26 percent fluoride and 0.1 percent fluoride varnish categories.
2.26 percent fluoride varnish—The panel identified 17 randomized and five 
nonrandomized clinical trials that evaluated 2.26 percent fluoride varnish. There were six 
randomized11-13,15-19 and two nonrandomized20,21 clinical trials concerning the primary 
dentition, 11 randomized11-13,22-32 and two nonrandomized33,34 clinical trials concerning 
the permanent dentition and one controlled35 clinical trial that combined results for both 
dentitions. The interventions for the control groups were no treatment, oral health 
counseling or placebo varnish. The studies were carried out in populations with various 
levels of dental caries. The studies were conducted in many countries (Brazil, Canada, Hong 
Kong, India, Kuwait, Netherlands, Poland, Spain, Sweden, United Kingdom and United 
States) in participants with and without additional fluoride use or other fluoride exposures 
(although most studies were conducted in low-fluoride areas) and with and without prior 
prophylaxis. The ages of the children at baseline varied from 6 months to 8 years for studies 
of the primary teeth; and from 5 to 15 years for studies of the permanent teeth. The panel 
identified two studies30,31 of root caries. The age range in these two studies was 44 to 79 
years. The varnish was applied professionally every three to 12 months; in most of studies, 
the varnish was applied every six months.
Because of the low risk of experiencing harm in children younger than 6 years, unit doses of 
2.26 percent fluoride varnish are the only topical fluoride agents that are recommended for 
this age group, even though other topical fluorides may have some evidence of a benefit. 
The panel had a moderate level of certainty that there is a benefit of 2.26 percent fluoride 
varnish in the permanent teeth of children aged 6 through 18 years. Although there were no 
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studies of coronal caries prevention in adults older than 18 years, the panel extrapolated the 
data from 6- through 18-year-olds to recommend using 2.26 percent varnish for this age 
group for both coronal and root caries. The benefits were judged to outweigh the potential 
for harm for all age groups.
0.1 percent fluoride varnish—The panel identified two nonrandomized clinical 
trials36,37 in which investigators evaluated 0.1 percent fluoride varnish on the primary 
dentition and one randomized clinical trial38 in which investigators evaluated 0.1 percent 
fluoride varnish in the permanent dentition. The control groups received oral hygiene 
instruction or no treatment. The studies were carried out in Germany and Sweden in 
populations with various baseline levels of dental caries. The ages of the children at baseline 
varied from 4 through 5 years for primary dentition and 9 through 12 years for permanent 
dentition. The varnish was applied professionally every six months in the primary dentition 
and every four months in the permanent dentition. Additional fluoride use or other fluoride 
exposure was variable, and all studies included prior prophylaxis.
The panel found evidence of no benefit from use of 0.1 percent fluoride varnish in children. 
Although there were no studies regarding coronal caries prevention in adults older than 18 
years, the panel extrapolated the data from 6- through 18-year-olds that showed no benefit of 
0.1 percent varnish for this age group. The panel was not comfortable extrapolating these 
results to root caries and gives no clinical recommendation for this form of the disease.
1.23 percent fluoride (APF) gel
The panel identified 11 randomized5,40-50 and four nonrandomized35,51-55 clinical trials that 
evaluated 1.23 percent fluoride (APF) gel quarterly, semiannually, annually or biannually 
(one application was observed after two years). The comparison groups received no 
treatment, a placebo, prophylaxis or a nonfluoride placebo gel. All studies except one51 
involved permanent teeth. In all of the studies, investigators applied fluoride gel for four 
minutes. All of the studies involved school-aged children (from 3 through 16 years) except 
for one.49 This study involved noninstitutionalized adults who were at least 60 years of age, 
and investigators reported on root caries. Ten studies40-45,48,49,51-55 were conducted in the 
United States and five elsewhere (India,35,50 United Kingdom,46 China5 and Canada47).
Although the panel had a low level of certainty that there was a benefit in using 1.23 percent 
fluoride (APF) gel in the primary dentition of children younger than 6 years, they judged 
that the potential for harm associated with swallowing APF gel could outweigh these 
benefits. The panel had a moderate level of certainty that there was a benefit of using 1.23 
percent fluoride (APF) gel in the permanent teeth of children aged 6 through 18 years. The 
panel found no studies regarding the effect of 1.23 percent fluoride (APF) gel on coronal 
caries of adults older than 18 years, but they extrapolated the evidence from permanent teeth 
of children 6 through 18 years of age to recommend (at the strength of expert opinion) for 
this age group.
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Prophylaxis before APF gel application
Although the panel searched the literature for prophylaxis before any topical fluoride 
application (per the second clinical question), it only found studies regarding prophylaxis 
before application of 1.23 percent fluoride (APF) gel. The panel identified two 
randomized56-58 and one nonrandomized59 clinical trials in which investigators assessed 
whether prophylaxis before professional application of APF gel affects its efficacy. Two 
studies were conducted in the United States,57-59 and one was conducted in Canada.56 All of 
the studies involved children aged 6 through 14 years at baseline. Investigators for both 
studies reported data regarding permanent teeth, and investigators for one56 also reported 
data regarding primary teeth.
The panel found no benefit for performing prophylaxis before the application of 1.23 
percent fluoride (APF) gel for the primary and permanent dentition of children. Although no 
studies were found in this category regarding adult populations, the panel extrapolated the 
evidence from the permanent teeth of children aged 6 through 18 years to coronal caries in 
adults, but it was not comfortable doing so for root caries and gives no clinical 
recommendation for this form of the disease.
1.23 percent fluoride (APF) foam
The panel identified two randomized clinical trials5,6 that evaluated 1.23 percent fluoride 
(APF) foam in children aged 3 through 7 years at baseline. One study involved the primary 
dentition6 and the other the permanent dentition.5 The comparison groups received either no 
treatment or placebo. Both studies were conducted in China.
Although a benefit was found with using 1.23 percent fluoride (APF) foam in children 
younger than 6 years, the panel judged that the potential for harm—including swallowing 
APF foam—outweighed this benefit. The panel found no benefit regarding caries prevention 
in the permanent dentition of children. The panel extrapolated this finding to permanent 
teeth in adults and does not recommend foam use in adults older than 18 years. The panel 
was not comfortable extrapolating these results to root caries and gives no clinical 
recommendation for this form of the disease.
Prophylaxis pastes containing fluoride
The panel identified three randomized60-62 and three nonrandomized63-65 clinical trials in 
which investigators evaluated the annual or semiannual application of prophylaxis pastes, 
most of which contained 1.23 percent fluoride (APF), for caries prevention. These studies 
were conducted between 1966 and 1980. The comparison groups received placebo 
prophylaxis pastes. All studies except one65 (regarding children aged 3-5 years at baseline) 
involved the permanent teeth of children aged 8 through 16 years at baseline.
The panel found no benefit of using prophylaxis pastes containing fluoride on the primary or 
permanent teeth of children. Although no studies were found regarding adult populations, 
the panel extrapolated the evidence of no benefit to coronal caries in adults but was not 
comfortable doing so for root caries and gives no clinical recommendation for this form of 
the disease.
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Prescription-strength, home-use (0.5 percent fluoride) gels or pastes
The panel reviewed the data for prescription-strength, home-use gels and pastes together. 
The primary difference between gels and pastes is that pastes contain a small amount of an 
abrasive component. The panel noted that investigators in only one study66 evaluated 
prescription-strength fluoride paste or gel (in this case, it was paste) in an unsupervised 
home environment, rather than by professional application in trays or with floss or in a 
supervised school setting. These products are often used at home and applied with a 
toothbrush.
The panel identified eight randomized66-75 and one nonrandomized76 clinical trials that met 
the inclusion criteria regarding prescription-strength (0.5 percent fluoride) paste or gel for 
home use. Six of the studies66,69-73,75,76 involved permanent teeth, one67 involved root 
caries, and two71,72,74 involved primary teeth. The comparison group for all studies was 
either placebo, 0.125-0.145 percent fluoride paste or no treatment. The baseline age range of 
children was 2 through 15 years for most of the studies, and one study included participants 
older than 75 years.67 The studies were performed in Denmark, French Polynesia, 
Netherlands, Sweden and the United States.
Although the panel found a benefit with 0.5 percent fluoride paste or gel treatment in 
children younger than 6 years, it judged that the potential for harm—including swallowing 
gels or pastes—outweighed this benefit. The panel had a low level of certainty regarding the 
benefit of 0.5 percent fluoride paste or gel on the permanent teeth of children and on root 
caries because there were few data on the home use of these products. However, the panel 
judged that the benefits outweighed potential harm. Although the panel found no studies in 
this category regarding permanent teeth in adults, the panel extrapolated the available 
evidence and judged that the benefits outweighed the potential for harm in this age group.
Prescription-strength, home-use (0.09 percent fluoride) mouthrinse
The panel identified 10 randomized77-88 and two nonrandomized89,90 clinical trials in which 
investigators evaluated 0.09 percent fluoride mouthrinse applications with daily, weekly or 
biweekly applications. Investigators in most of the studies compared the intervention with 
placebo mouthrinses, although some compared the intervention with no treatment85,89 or 
oral hygiene instruction and prophylaxis.79 All studies were conducted on permanent teeth. 
All of the studies but one87 were conducted in school-aged children (5 through 12 years). No 
adult populations were studied except elderly people living in long-term care facilities 
(mean age, 83 years) in one study.87 In most studies, the children's teachers supervised the 
use of the fluoride rinse. In only one study88 were children enrolled on the basis of their 
caries risk status. Four of the studies77,78,80-82,84 were conducted in the United States. The 
other studies were conducted in Canada,87 Denmark,83 New Zealand,79-88 Philippines,90 
South Africa86,89 and Sweden.85
The panel judged that the benefits outweighed the potential for harm in children 6 years or 
older and adults. Although there were no studies regarding the effect of 0.09 percent fluoride 
mouthrinse on caries in children younger than 6 years, the panel judged that the risk of 
swallowing mouthrinse outweighed the potential for unknown benefits. Although there were 
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no studies regarding coronal caries in adults older than 18 years, the panel extrapolated the 
results from children aged 6 through 18 years to arrive at a clinical recommendation based 
on expert opinion.
GENERAL REMARKS ON CLINICAL RECOMMENDATIONS
A practitioner should consider a patient's risk of experiencing disease when developing an 
optimal caries-prevention plan. Part of a patient's risk status includes whether the patient 
lives in an optimally fluoridated community and uses fluoridated toothpaste. Patients at low 
risk of developing caries may not need additional fluoride interventions, whereas caries in 
people at high risk of developing caries appears at times to be refractory to additional 
intensive preventive interventions.91,92
Professional judgment is required to interpret the clinical relevance of preventive measures 
for individual patients. The combination of evidence from clinical studies, the patient's 
caries risk status, the practitioner's professional judgment and the patient's needs and 
preferences should guide decision making. Patient education, assessment of readiness for 
change, dietary advice, other preventive modalities and periodic clinical examinations 
should be considered as a part of the caries-prevention plan. In public health care settings, 
additional considerations include the feasibility and cost of the proposed intervention. The 
panel did not consider these issues when providing its clinical recommendations.
The panel noted that clinical trials generally test the efficacy of an intervention, which 
results in the best possible outcome for the intervention because of the controlled nature of 
the trial and strict inclusion and exclusion criteria for participants. These results do not 
necessarily reflect the effectiveness of an intervention (that is, how the intervention works in 
routine practice), which typically includes patients with comorbidities who may be taking 
multiple medications. Under controlled study conditions, the efficacy is almost always 
higher than the effectiveness because of the presence of idealized conditions.
The panel has reported on several different topical fluoride agents, including those planned 
for home use. Practitioners can expect different compliance with treatment plans 
incorporating home-use products than with professionally applied products. Cost, efficacy or 
effectiveness related to the intended usage environment also may vary.
When considering any intervention, the practitioner and patient must balance the potential 
benefits with the potential harm. The panel considered harm reported by investigators of the 
included articles as well as known potential harm of fluoride use. Potential harm of topical 
fluorides includes, but may not be limited to, nausea and vomiting associated with the 
ingestion of topical fluorides93 and dental fluorosis (an esthetic concern) while tooth enamel 
is developing (until about age 6 years) due to daily ingestion of topical fluoride, such as 
from toothpaste or from prescription-strength, home-use gels. There is less of a concern 
about professionally applied topical fluorides for which there are longer intervals between 
applications.94 Fluoride varnish dispensed in unit doses has lower potential for harm than do 
other forms of high-concentration topical fluoride agents, because the amount of fluoride 
that is placed in the mouth by means of fluoride varnish is approximately one-tenth that of 
other professionally applied products.95
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The panel recommends that multiple well-designed, appropriately powered, placebo-
controlled randomized trials that follow the Consolidated Standards of Reporting Trials 
guidelines96 with standardized reporting according to age, dentition and caries risk status be 
conducted in the United States. Standard methodologies for caries and fluoride randomized 
controlled trials should be developed. The panel recommends that future trials be registered 
with ClinicalTrials.gov or equivalent registries. Specific areas of research recommendations 
are as follows:
– Mechanisms of fluoride action and effects. Research is needed regarding various 
topical fluorides to determine their mechanism of action and caries-preventive effects 
when in use at the current level of background fluoride exposure (that is, fluoridated 
water and fluoride toothpaste) in the United States. Studies regarding strategies for 
using fluoride to induce arrest or reversal of caries progression, as well as topical 
fluoride's specific effect on erupting teeth, also are needed.
– Populations. Research is needed concerning the following subpopulations: adults 
aged 18 through 65 years, high-risk adults older than 65 (including those living in long-
term care facilities) who are at high risk of developing caries, children and adults who 
are at extremely high risk of developing caries, U.S.-specific populations, special needs 
populations (for example, those with cognitive disabilities, compromised self-care 
abilities or physical disabilities) and populations with chronic diseases (such as Sjögren 
syndrome). Comparative effectiveness studies of different fluoride strategies in these 
populations, as well as studies regarding strategies to manage xerostomia-induced 
coronal and root caries also are needed.
– Products and usage. Research is needed concerning the effectiveness and risks of 
specific products in the following areas: self-applied, prescription-strength, home-use 
fluoride gels, toothpastes or drops; 2 percent professionally applied sodium fluoride gel; 
alternative delivery systems, such as foam; optimal application frequencies for fluoride 
varnish and gels; one-minute applications of APF gel; and combinations of products 
(home-use and professionally applied).
– Measurement and outcomes. Development of measurements to evaluate caries arrest 
and reversal are needed.
– Economics. Studies regarding caries prevention and the economic benefit of topical 
fluoride in different caries risk populations are needed.
– Dissemination and implementation. Research on the best ways to help practitioners 
incorporate clinical recommendations into practice are needed.
CONCLUSIONS
The panel recommends the following for people at risk of developing dental caries: 2.26 
percent fluoride varnish or 1.23 percent fluoride (APF) gel; or prescription-strength, home-
use 0.5 percent fluoride gel or paste or 0.09 percent fluoride mouthrinse for patients 6 years 
or older. Only 2.26 percent fluoride varnish is recommended for children younger than 6 
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years. The strengths of the recommendations for the recommended products varied from “in 
favor” to “expert opinion for.” As part of the evidence-based approach to care, these clinical 
recommendations should be integrated with the practitioner's professional judgment and the 
patient's needs and preferences.
ABBREVIATION KEY
ADA American Dental Association
APF Acidulated phosphate fluoride
CSA Council on Scientific Affairs
USPSTF U.S. Preventive Services Task Force
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TABLE 1
Definitions for levels of certainty.
*
LEVEL OF CERTAINTY DEFINITION
High This statement is strongly established by the best available evidence; the conclusion is unlikely to be affected 
strongly by the results of future studies.
Moderate This statement is based on preliminary determination from the current best available evidence; as more 
information becomes available, the magnitude or direction of the observed effect could change, and this change 
could be large enough to alter the conclusion.
Low The available evidence is insufficient to support the statement, or the statement is based on extrapolation from 
the best available evidence; more information could allow a reliable estimation of effects on health outcomes.
*
For more details, see American Dental Association Center for Evidence-Based Dentistry.2 Adapted from the U.S. Preventive Services Task Force 
system.3
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TABLE 2
Balancing level of certainty and net benefit rating to arrive at recommendation strength.
*
LEVEL OF CERTAINTY NET BENEFIT RATING
Benefit Outweighs Potential 
Harm
Benefit Balanced With 
Potential Harm
No Benefit, Potential Harm 
Outweighs Benefit
High Strong In favor Against
Moderate In favor Weak Against
Low Expert opinion for
†
 or expert opinion against
†
*
Adapted from the U.S. Preventive Services Task Force (USPSTF) system.3
†
The USPSTF system defines this category of evidence as “insufficient”; “grade I indicates that the evidence is insufficient to determine the 
relationship between benefits and harms (i.e., net benefit).” The corresponding recommendation grade “I” is defined as follows: “The USPSTF 
concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or 
conflicting, and the balance of benefits and harms cannot be determined.”
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TABLE 3
Definitions for the strength of clinical
*
RECOMMENDATION STRENGTH DEFINITION
Strong Evidence strongly supports providing this intervention.
In Favor Evidence favors providing this intervention.
Weak Evidence suggests implementing this intervention after alternatives have been considered.
Expert Opinion For
† Evidence is lacking; the level of certainty is low. Expert opinion guides this recommendation
Expert Opinion Against
† Evidence is lacking; the level of certainty is low. Expert opinion suggests not implementing this 
intervention.
Against Evidence suggests not implementing this intervention or discontinuing ineffective procedures.
*
Adapted from the U.S. Preventive Services Task Force (USPSTF) system.3
†
The USPSTF system defines this category of evidence as “insufficient”; “grade I indicates that the evidence is insufficient to determine the 
relationship between benefits and harms (i.e., net benefit).” The corresponding recommendation grade “I” is defined as follows: “The USPSTF 
concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or 
conflicting, and the balance of benefits and harms cannot be determined.”
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TABLE 4
Clinical recommendations for use of professionally applied or prescription-strength, home-use topical fl 
uorides for caries prevention in patients at elevated risk of developing caries.
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TABLE 6
Fluoride ion and sodium fluoride concentrations in topical fluoride agents.
TOPICAL FLUORIDE AGENT FLUORIDE ION, % SODIUM FLUORIDE, %
Professionally Applied
2.26 Percent fluoride varnish 2.26 5.0
APF
*
 gel (with 0.1 molar phosphoric acid)
1.23 2.7





Prophylaxis paste containing fluoride (most as APF) 1.23 2.7
0.1 Percent fluoride varnish
0.1
‡ Not applicable
Prescription Strength, Home Use
Prescription-strength gels or pastes with or without acidulation (0.1 M phosphoric 
acid)
0.5 1.1
Prescription-strength mouthrinses 0.09 0.2
*
APF: Acidulated phosphate fluoride.
†
Concentration of fluoride before being dispensed. When delivered as a foam by combining gel with air, the total amount of fluoride in the foam 
product is reduced.
‡
The fluoride ion form was 0.09 percent difluorsilane.
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